Harrow (HROW) Stock Price, News & Analysis

Company Overview

Harrow, Inc. is an ophthalmic pharmaceutical company focused on developing, acquiring, and commercializing products for the treatment of eye conditions and for use in ophthalmic procedures. The company serves ophthalmologists, optometrists, ambulatory surgery centers, and other eye-care providers, primarily in the United States.

Harrow’s portfolio includes VEVYE, a cyclosporine ophthalmic emulsion indicated for the treatment of signs and symptoms of dry eye disease, and IHEEZO, a chloroprocaine hydrochloride ophthalmic gel used to provide topical ocular anesthesia during ophthalmic procedures. The company also markets and develops additional prescription ophthalmic products and therapies through its commercial and pharmaceutical operations.

The company was founded as Harrow Health and later adopted the Harrow name as it expanded its ophthalmic pharmaceutical business. Harrow is headquartered in Nashville, Tennessee, and is led by founder and Chief Executive Officer Mark L. Baum.

Key Stats

• Today's Range: $32.58 to $33.28
• 50-Day Range: $33.07 to $44.45
• 52-Week Range: $28.54 to $54.85
• Volume: 372,703 shs
• Average Volume: 523,899 shs
• Market Capitalization: $1.24 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $66.71
• Consensus Rating: Moderate Buy

Harrow Stock Analysis - MarketRank™

Harrow scored higher than 48% of companies evaluated by MarketBeat, and ranked 586th out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.1 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Harrow has received a consensus rating of Moderate Buy. The company's average rating score is 2.64, and is based on no strong buy ratings, 8 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Harrow has a consensus price target of $66.71, representing about 101.7% upside from its current price of $33.07.

Amount of Analyst Coverage

Harrow has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Harrow is -33.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Harrow is -33.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Harrow has a P/B Ratio of 23.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

22.91% of the float of Harrow has been sold short.

Short Interest Ratio / Days to Cover

Harrow has a short interest ratio ("days to cover") of 15.68, which indicates bearish sentiment.

Change versus previous month

Short interest in Harrow has recently increased by 10.46%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Harrow does not currently pay a dividend.

Dividend Growth

Harrow does not have a long track record of dividend growth.

News and Social Media

• Score: 3.1 / 5
• News Sentiment: 0.89

News Sentiment

Harrow has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Harrow this week, compared to 5 articles on an average week.

Search Interest

Only 2 people have searched for HROW on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.

MarketBeat Follows

1 people have added Harrow to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.9 / 5
• Insider Trading: Selling Shares

Insider Buying vs. Insider Selling

In the past three months, Harrow insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $450,000.00 in company stock.

Percentage Held by Insiders

12.80% of the stock of Harrow is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

72.76% of the stock of Harrow is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/10/2026
• Today: 9/26/2026
• Next Earnings (Estimated): 11/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:HROW
• Previous Symbol: NASDAQ:HROW
• CIK: 1360214
• Web: www.harrow.com
• Phone: (615) 733-4730
• Fax: 858-345-1745
• Employees: 373
• Year Founded: 2012

Price Target and Rating

• Average Price Target for Harrow: $66.71
• High Price Target: $88.00
• Low Price Target: $45.00
• Potential Upside/Downside: +101.7%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.64
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$5.14 million
• Net Margins: -13.51%
• Pretax Margin: -12.13%
• Return on Equity: -38.00%
• Return on Assets: -3.37%

Debt

• Debt-to-Equity Ratio: 19.70
• Current Ratio: 2.24
• Quick Ratio: 2.08

Sales & Book Value

• Annual Sales: $272.30 million
• Price / Sales: 4.55
• Cash Flow: $0.86 per share
• Price / Cash Flow: 38.30
• Book Value: $1.41 per share
• Price / Book: 23.45

Miscellaneous

• Outstanding Shares: 37,490,000
• Free Float: 32,690,000
• Market Cap: $1.24 billion
• Optionable: Optionable
• Beta: 0.24